Literature DB >> 8615431

Agranulocytosis after addition of risperidone to clozapine treatment.

L S Godleski, M J Sernyak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8615431     DOI： 10.1176/ajp.153.5.735b

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  11 in total

1.  Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents.

Authors:  Frank Gianfrancesco; Michael B Durkin; Ramy Mahmoud; Ruey-Hua Wang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.

Authors:  Constantin Tranulis; Leila Skalli; Pierre Lalonde; Luc Nicole; Emmanuel Stip
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 3.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 5.  [Augmenting atypical antipsychotic medications with clozapin].

Authors:  M Zink; H Dressing
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

Review 6.  Risperidone augmentation of clozapine: a critical review.

Authors:  Vassilis P Kontaxakis; Panayotis P Ferentinos; Beata J Havaki-Kontaxaki; Konstantinos G Paplos; Dimitra A Pappa; George N Christodoulou
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08-08       Impact factor: 5.270

Review 7.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

8.  In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation.

Authors:  Manoranjenni Chetty; Fabrizio d'Esposito; Wei V Zhang; John Glen; Glenys Dore; Zvijezdana Stankovic; Robert J Edwards; Iqbal Ramzan; Michael Murray
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

9.  A case with neutropenia related with the use of various atypical antipsychotics.

Authors:  Myung Ho Lim; Jong-Il Park; Tae Won Park
Journal:  Psychiatry Investig       Date:  2013-12-16       Impact factor: 2.505

10.  Late Onset Agranulocytosis with Clozapine Associated with HLA DR4 Responding to Treatment with Granulocyte Colony-stimulating Factor: A Case Report and Review of Literature.

Authors:  Aakanksha Singh; Sandeep Grover; Pankaj Malhotra; Subhash C Varma
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-05-31       Impact factor: 2.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.